BACKGROUND: The aim of this study was to examine the expression of vascular endothelial growth factor receptor-2 (VEGFR-2) in Merkel cell carcinoma (MCC) and to correlate the expression with tumour growth and the development of metastasis. PATIENTS AND METHODS: The study included 21 patients treated for MCC at Helsinki University Hospital, Helsinki, Finland between 1987 and 2003. The VEGFR-2 expression was studied by immunohistochemistry. The correlations between the quantitative expression of VEGFR-2 and tumour size and metastatic dissemination were analyzed statistically. RESULTS: VEGFR-2 was expressed in 91% of the large (> or =2 cm) and 70% of the small (<2 cm) tumours. There was a stronger positive correlation between expression of VEGFR-2 and tumour size than between VEGFR-2 and metastatic potential. CONCLUSION: A correlation between the expression of pro-angiogenic marker and tumour size was established. Our results indicate that inhibiting angiogenesis could be a treatment option for MCC. The role of neovascularization in the metastatic process in MCC remains to be determined.
BACKGROUND: The aim of this study was to examine the expression of vascular endothelial growth factor receptor-2 (VEGFR-2) in Merkel cell carcinoma (MCC) and to correlate the expression with tumour growth and the development of metastasis. PATIENTS AND METHODS: The study included 21 patients treated for MCC at Helsinki University Hospital, Helsinki, Finland between 1987 and 2003. The VEGFR-2 expression was studied by immunohistochemistry. The correlations between the quantitative expression of VEGFR-2 and tumour size and metastatic dissemination were analyzed statistically. RESULTS:VEGFR-2 was expressed in 91% of the large (> or =2 cm) and 70% of the small (<2 cm) tumours. There was a stronger positive correlation between expression of VEGFR-2 and tumour size than between VEGFR-2 and metastatic potential. CONCLUSION: A correlation between the expression of pro-angiogenic marker and tumour size was established. Our results indicate that inhibiting angiogenesis could be a treatment option for MCC. The role of neovascularization in the metastatic process in MCC remains to be determined.
Authors: A Bob; F Nielen; J Krediet; J Schmitter; D Freundt; D Terhorst; J Röwert-Huber; J Kanitakis; E Stockfleth; Ch Ulrich; M Weichenthal; F Egberts; B Lange-Asschenfeldt Journal: J Cancer Res Clin Oncol Date: 2017-06-21 Impact factor: 4.553
Authors: Guilherme Rabinowits; Cecilia Lezcano; Paul J Catalano; Patricia McHugh; Hailey Becker; Megan M Reilly; Julian Huang; Ayushi Tyagi; Manisha Thakuria; Scott C Bresler; Lynette M Sholl; Geoffrey I Shapiro; Robert Haddad; James A DeCaprio Journal: Oncologist Date: 2018-02-14
Authors: Cecilia Lezcano; Sonja Kleffel; Nayoung Lee; Allison R Larson; Qian Zhan; Andrew DoRosario; Linda C Wang; Tobias Schatton; George F Murphy Journal: Lab Invest Date: 2014-08-11 Impact factor: 5.662
Authors: Erica S Tarabadkar; Hannah Thomas; Astrid Blom; Upendra Parvathaneni; Thomas Olencki; Paul Nghiem; Shailender Bhatia Journal: Am J Case Rep Date: 2018-04-30
Authors: Karolina Stachyra; Monika Dudzisz-Śledź; Elżbieta Bylina; Anna Szumera-Ciećkiewicz; Mateusz J Spałek; Ewa Bartnik; Piotr Rutkowski; Anna M Czarnecka Journal: Int J Mol Sci Date: 2021-06-11 Impact factor: 5.923
Authors: Elena Dellambra; Maria Luigia Carbone; Francesca Ricci; Francesco Ricci; Francesca Romana Di Pietro; Gaia Moretta; Sofia Verkoskaia; Elisa Feudi; Cristina M Failla; Damiano Abeni; Luca Fania Journal: Biomedicines Date: 2021-06-23